Biologics Characterization: Intact and Subunit Mass Analysis

Jul 20, 2018 | Biopharma, Blogs | 0 comments

When All You Need Is Range – Mass Range, Dynamic Range, and the Complete Range

Launching the best possible product in the shortest time possible is key for pharmaceutical companies like you. As you know, nearly every process throughout the biologics development cycle requires an immense amount of analytical characterization; get these processes right and significantly reduce time-to-market.

This blog explores a wide range of biologics characterizations, including intact and subunit protein analysis, to help you address your challenges. For more details, fill out the form on your right to download the full Biotherapeutic Analytical Characterization eBook.

Safeguarding Biotherapeutic Product Quality
The ability to routinely and accurately measure intact and subunit protein mass is a critical step in demonstrating the quality and stability of biologics. Using the appropriate combination analytical methods and techniques can result in significant time and cost savings during product development, obtaining regulatory approval and scaling-up manufacturing.

But biotherapeutics are inherently complex and these large class protein biologics, such as monoclonal antibodies (mAb), are significantly more difficult to characterize than small molecules. Liquid Chromatography-Mass Spectrometry (LC-MS) and Capillary Electrophoresis Electrospray Ionization-Mass Spectrometry (CESI-MS) have become recognized techniques for biotherapeutic characterization, offering the resolution, sensitivity, and speed to deliver better results and improve lab productivity.

The Complete Range from SCIEX
SCIEX has a range of next-generation technology with the mass range and dynamic range needed to simultaneously detect major and minor isoforms in your intact biotherapeutic. The easy, point-and-click interface of SCIEX OS on the X500B QTOF system makes setup rapid and simple. Or dig deeper into your biotherapeutic products with the high-performance TripleTOF® 6600 System. Our BioPharmaView™ Software balances power and simplicity to bring routine, fast and accurate intact and subunit analysis by mass spectrometry to all laboratories1.

We demonstrate the pure performance, robustness, and stability of our solutions in the Biotherapeutic Analytical Characterization eBook, packed with a range of tech notes and solutions guides, covering:

  • Intact Mass Analysis without Compromise on TripleTOF Mass Spectrometry Platforms
  • Detection of Intact Antibody Impurities
  • Analysis of Intact mAbs using MicroLC with the TripleTOF 6600 System
  • Comparative Multi-Supplier Lot Analysis of Trastuzumab using Subunit Analysis
  • Monitoring Antibody Oxidation at the Subunit Level
  • Structural Characterization of ADCs by Combination of Intact, Middle-Up and Bottom-Up Approaches

If you want to accelerate the biologics development cycle and reduce your time-to-market with fast, accurate, and robust intact and subunit mass analysis, fill out the form on your right to download the Biotherapeutic Analytical Characterization eBook.

1https://www.technologynetworks.com/biopharma/articles/mass-spectrometry-in-biopharmaceutical-discovery-303219

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial